Aurinia Pharmaceuticals (IKAP) Ownership - Who Owns Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (IKAP) Ownership Overview
- 12.79% Insiders
- 6.08% Mutual Funds
- 0.60% Other Institutional Investors
- 7.43% ETFs
- 73.10% Public Companies and Individual Investors
The ownership structure of Aurinia Pharmaceuticals (DE:IKAP) stock is a mix of institutional, retail, and individual investors. Approximately 14.10% of the company’s stock is owned by Institutional Investors, 12.79% is owned by Insiders, and 73.10% is owned by Public Companies and Individual Investors.
The ownership structure of Aurinia Pharmaceuticals (DE:IKAP) stock is a mix of institutional, retail, and individual investors. Approximately 14.10% of the company’s stock is owned by Institutional Investors, 12.79% is owned by Insiders, and 73.10% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 10, 2026 | Stephen P. Robertson | $190,427 | |
| Jun 01, 2026 | Kevin Tang | $12,455,227 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Kevin Tang | 13,044,106 | Insider | 9.80% | 216,545,204 |
| Ishares | 5,832,595 | Institution | 4.38% | 96,826,910 |
| Tiaa-cref Funds | 2,008,481 | Institution | 1.51% | 33,342,793 |
| Peter Greenleaf | 1,744,866 | Insider | 1.31% | 28,966,520 |
| Fidelity Salem Street Trust | 1,414,907 | Institution | 1.06% | 23,488,871 |
| Goldman Sachs Trust | 1,293,241 | Institution | 0.97% | 21,469,094 |
| Vanguard | 1,266,444 | Institution | 0.95% | 21,024,237 |
| Vanguard Scottsdale Funds | 824,227 | Institution | 0.62% | 13,682,992 |
| Matthew Maxwell Donley | 662,900 | Insider | 0.50% | 11,004,803 |
| Stephen P. Robertson | 588,848 | Insider | 0.44% | 9,775,466 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Tiaa-cref Funds | 2,008,481 | Institution | 1.51% | 33,342,793 |
| Fidelity Salem Street Trust | 1,414,907 | Institution | 1.06% | 23,488,871 |
| Goldman Sachs Trust | 1,293,241 | Institution | 0.97% | 21,469,094 |
| Vanguard Scottsdale Funds | 824,227 | Institution | 0.62% | 13,682,992 |
| Schwab Capital Trust | 476,649 | Institution | 0.36% | 7,912,850 |
| Vanguard World Fund | 323,930 | Institution | 0.24% | 5,377,562 |
| Federated Hermes Mdt Series | 237,798 | Institution | 0.18% | 3,947,685 |
| Hussman Investment Trust | 210,000 | Institution | 0.16% | 3,486,210 |
| Sei Institutional Managed Trust | 126,678 | Institution | 0.10% | 2,102,981 |
| Diamond Hill Funds | 92,212 | Institution | 0.07% | 1,530,811 |
FAQ
Who Owns Aurinia Pharmaceuticals (DE:IKAP)?
According to the latest TipRanks data, approximately 14.10% of the company's stock is held by institutional investors, 12.79% is held by insiders, and 73.10% is held by public companies and individual investors.
What percentage of Aurinia Pharmaceuticals (DE:IKAP) stock is held by institutional investors?
According to the latest TipRanks data, approximately 14.10% of Aurinia Pharmaceuticals (DE:IKAP) stock is held by institutional investors: 6.08% by mutual funds, 7.43% by ETFs and 0.60% by other institutional investors.
What percentage of Aurinia Pharmaceuticals (DE:IKAP) stock is held by retail investors?
According to the latest TipRanks data, approximately 73.10% of Aurinia Pharmaceuticals (DE:IKAP) stock is held by public companies and individual investors.
Who owns the most shares of Aurinia Pharmaceuticals (DE:IKAP)?
Kevin Tang owns the most shares of Aurinia Pharmaceuticals (DE:IKAP).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.